Efficacy of selpercatinib after prior systemic therapy in patients with RET mutant medullary thyroid cancer.

被引：3
|
作者：
Wirth, Lori J.
Sherman, Eric Jeffrey
Weiler, Daniela
Cabanillas, Maria E.
Robinson, Bruce
Italiano, Antoine
Laskin, Janessa J.
Subbiah, Vivek
Drilon, Alexander E.
Soldatenkova, Victoria
French, Pearl Plernjit
Wright, Jennifer
Kroiss, Matthias
Shah, Manisha H.
机构：
[1] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Kantonsspital Luzern, Arth, Switzerland
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Royal North Shore Hosp, St Leonards, NSW, Australia
[6] Inst Bergonie, Early Phase Trials Unit, Bordeaux, France
[7] Univ British Columbia, BC Canc, Vancouver, BC, Canada
[8] Weill Cornell Med Coll, New York, NY USA
[9] Eli Lilly & Co, Indianapolis, IN 46285 USA
[10] Univ Utah, Salt Lake City, UT USA
[11] Univ Hosp Wuerzburg, Wurzburg, Germany
[12] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.6074
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6074
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer.
    Shah, Manisha H.
    Sherman, Eric Jeffrey
    Robinson, Bruce
    Solomon, Benjamin J.
    Kang, Hyunseok
    Lorch, Jochen H.
    Worden, Francis P.
    Brose, Marcia S.
    Leboulleux, Sophie
    Godbert, Yann
    Meurer, Marie
    Morris, John C.
    Owonikoko, Taofeek Kunle
    Tan, Daniel Shao-Weng
    Gautschi, Oliver
    Patel, Jyoti D.
    Yang, Luxi
    Kherani, Jennifer
    Cabanillas, Maria E.
    Wirth, Lori J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer (MTC)
    Shah, M.
    Sherman, E.
    Robinson, B.
    Solomon, B.
    Kang, H.
    Lorch, J.
    Worden, F.
    Brose, M.
    Leboulleux, S.
    Godbert, Y.
    Meurer, M.
    Morris, J.
    Owonikoko, T.
    Tan, D. S. -W.
    Gautschi, O.
    Patel, J.
    Yang, L.
    Kherani, J.
    Cabanillas, M.
    Wirth, L.
    Weiler, D.
    SWISS MEDICAL WEEKLY, 2020, : 7S - 8S
  • [3] Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
    Hadoux, J.
    Elisei, R.
    Brose, M. S.
    Hoff, A. O.
    Robinson, B. G.
    Gao, M.
    Jarzab, B.
    Isaev, P.
    Kopeckova, K.
    Wadsley, J.
    Fuehrer, D.
    Keam, B.
    Bardet, S.
    Sherman, E. J.
    Tahara, M.
    Hu, M. I.
    Singh, R.
    Lin, Y.
    Soldatenkova, V
    Wright, J.
    Lin, B.
    Maeda, P.
    Capdevila, J.
    Wirth, L. J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (20): : 1851 - 1861
  • [4] Selpercatinib - First-line in advanced progressive RET-mutant medullary thyroid cancer
    Dolfi, Mathieu
    Bardet, Stephane
    BULLETIN DU CANCER, 2024, 111 (12) : 1082 - 1083
  • [5] Fluctuating obliterative bronchiolitis in RET-mutant medullary thyroid cancer patient treated with selpercatinib
    Gambale, Carla
    Prete, Alessandro
    Romei, Chiara
    Celi, Alessandro
    Elisei, Rossella
    Matrone, Antonio
    EUROPEAN THYROID JOURNAL, 2024, 13 (05)
  • [6] Efficacy and safety with selpercatinib in patients with RET fusion plus NSCLC: Analysis by last prior systemic therapy
    Goto, Koichi
    Gautschi, Oliver
    Drilon, Alexander
    Tan, Daniel Shao Weng
    Oxnard, Geoffrey R.
    McCoach, Caroline
    Park, Keunchil
    Alonso Casal, G.
    de Braud, Filippo
    French, Pearl
    Soldatenkova, Victoria
    Besse, Benjamin
    ANNALS OF ONCOLOGY, 2021, 32 : S297 - S297
  • [7] LIBRETTO-531: Selpercatinib in patients with treatment (Tx)-naive RET-mutant medullary thyroid cancer (MTC)
    Hernando, J.
    Tarasova, V.
    Hu, M. I.
    Sherman, E. J.
    Brose, M. S.
    Robinson, B.
    Tahara, M.
    Wirth, L. J.
    Sashegyi, A.
    Soldatenkova, V.
    Lin, B. K.
    Wright, J.
    Hoff, A. O.
    Leboulleux, S.
    Elisei, R.
    Capdevila, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1091 - S1091
  • [8] Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases
    Andreev-Drakhlin, Alexander
    Cabanillas, Maria
    Amini, Behrang
    Subbiah, Vivek
    JCO PRECISION ONCOLOGY, 2020, 4 : 1302 - 1306
  • [9] Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients
    Zheng, Xiangqian
    Fang, Meiyu
    Fan, Yun
    Sun, Yuping
    Sun, Meili
    Yang, Ankui
    Zhang, Bin
    Liu, Qinjiang
    Liu, Hui
    Zhou, Xiaohong
    Huang, Tao
    Qin, Jianwu
    Wang, Zhaohui
    Qin, Mengmeng
    Shen, Zhenwei
    Yao, Sheng
    Yang, Jason
    Wang, Yu
    Gao, Ming
    ENDOCRINE-RELATED CANCER, 2024, 31 (04)
  • [10] Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib
    Elisei, Rossella
    Ciampi, Raffaele
    Matrone, Antonio
    Prete, Alessandro
    Gambale, Carla
    Ramone, Teresa
    Simeakis, George
    Materazzi, Gabriele
    Torregrossa, Liborio
    Ugolini, Clara
    Romei, Cristina
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (08): : 2195 - 2202
12345